Navigation Links
Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System
Date:11/12/2008

GOTHENBURG, Sweden, November 12 /PRNewswire/ -- Cellectricon, a leading provider of advanced screening solutions for drug discovery, has today received its most significant and largest single order to date. The order includes three Cellaxess(R)HT systems and the customer is a leading US biotech firm.

"An order of this magnitude proves the system's unique features and value, and validates Cellectricon's strategy to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations." says Jonas Ohlsson, CEO at Cellectricon. "Cellectricon has developed the Cellaxess(R)HT system in close collaboration with leading pharmaceutical companies and academic research groups to meet the rapidly growing demand for a true high throughput transfection screening technology, capable of reagent-free delivery of genetic material to biologically relevant cell types."

Cellaxess(R)HT is the world's first fully automated workstation for high throughput RNAi screening on biologically relevant cell types. The system enables reagent free delivery of siRNA and cDNA to a wide range of primary cells and cell lines with excellent efficiency and viability at a throughput of 50, 000 wells per day. Cellaxess(R)HT is first of its kind on the market and will significantly impact target discovery by providing key functional data in relevant primary human cells.

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology market. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

Contact Details:

Jonas Ohlsson, CEO

Phone: +46(0)709-73-47-92

E-mail: jonas.ohlsson@cellectricon.com

Susanne Fagerlund

VP Marketing & Communications

Phone: +46(0)31-760-35-15

E-mail: susanne.fagerlund@cellectricon.com


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
2. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
3. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
4. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
5. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
6. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
7. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
8. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
9. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
10. Environmental Tectonics Corporations Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices that can ... sports. On Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia ... at a Smart Talk session. Smart Talk will run from 8:30 – 10:30 ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to control cells — optogenetics — is key to exciting advances in the ... art, spatially patterned light projected via free-space optics stimulates small, transparent organisms and ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... 8, 2016 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... developing and commercializing products to treat rare diseases where ... it will be hosting an Investor Webcast Event Friday, ... origins of innate defense regulators (IDRs) as a new ... mucositis and the recently announced and published Phase 2 ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):